Oculis (NASDAQ:OCS) Issues Earnings Results

Oculis (NASDAQ:OCS) announced its quarterly earnings results on Tuesday. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.28), Zacks reports. Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%.

Oculis Trading Up 0.1 %

Shares of OCS traded up $0.03 during trading hours on Thursday, reaching $18.87. 16,883 shares of the company traded hands, compared to its average volume of 44,942. Oculis has a 12 month low of $10.55 and a 12 month high of $23.08. The company has a market capitalization of $764.11 million, a price-to-earnings ratio of -9.77 and a beta of 0.02. The company’s fifty day moving average price is $20.86 and its two-hundred day moving average price is $16.88. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Robert W. Baird boosted their price objective on shares of Oculis from $37.00 to $41.00 and gave the company an “outperform” rating in a research note on Thursday. HC Wainwright lowered their price objective on Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Chardan Capital reiterated a “buy” rating and issued a $28.00 target price on shares of Oculis in a research report on Thursday.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.